BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Högberg T, Frimurer TM, Sasmal PK. Melanin concentrating hormone receptor 1 (MCHR1) antagonists—Still a viable approach for obesity treatment? Bioorganic & Medicinal Chemistry Letters 2012;22:6039-47. [DOI: 10.1016/j.bmcl.2012.08.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Potter LE, Burgess CR. The melanin-concentrating hormone system as a target for the treatment of sleep disorders. Front Neurosci 2022;16:952275. [DOI: 10.3389/fnins.2022.952275] [Reference Citation Analysis]
2 Lim G, You KY, Lee JH, Jeon MK, Lee BH, Ryu JY, Oh KS. Identification and New Indication of Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist Derived from Machine Learning and Transcriptome-Based Drug Repositioning Approaches. Int J Mol Sci 2022;23:3807. [PMID: 35409167 DOI: 10.3390/ijms23073807] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kolur V, Vastrad B, Vastrad C, Kotturshetti S, Tengli A. Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis. BMC Cardiovasc Disord 2021;21:329. [PMID: 34218797 DOI: 10.1186/s12872-021-02146-8] [Reference Citation Analysis]
4 Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol 2020;11:554961. [PMID: 33776749 DOI: 10.3389/fphar.2020.554961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Morganstern I, Gulati G, Leibowitz SF. Role of melanin-concentrating hormone in drug use disorders. Brain Res 2020;1741:146872. [PMID: 32360868 DOI: 10.1016/j.brainres.2020.146872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Schaller D, Hagenow S, Alpert G, Naß A, Schulz R, Bermudez M, Stark H, Wolber G. Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. ACS Med Chem Lett 2017;8:648-53. [PMID: 28626527 DOI: 10.1021/acsmedchemlett.7b00118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
7 Diniz GB, Bittencourt JC. The Melanin-Concentrating Hormone as an Integrative Peptide Driving Motivated Behaviors. Front Syst Neurosci 2017;11:32. [PMID: 28611599 DOI: 10.3389/fnsys.2017.00032] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
8 Johansson A. Evolution of physicochemical properties of melanin concentrating hormone receptor 1 (MCHr1) antagonists. Bioorg Med Chem Lett 2016;26:4559-64. [PMID: 27595423 DOI: 10.1016/j.bmcl.2016.08.072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. J Med Chem 2016;59:2497-511. [PMID: 26741166 DOI: 10.1021/acs.jmedchem.5b01654] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
10 Igawa H, Takahashi M, Kakegawa K, Kina A, Ikoma M, Aida J, Yasuma T, Kawata Y, Ashina S, Yamamoto S, Kundu M, Khamrai U, Hirabayashi H, Nakayama M, Nagisa Y, Kasai S, Maekawa T. Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives. J Med Chem 2016;59:1116-39. [PMID: 26736071 DOI: 10.1021/acs.jmedchem.5b01704] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Karlsson S, Bergman R, Löfberg C, Moore PR, Pontén F, Tholander J, Sörensen H. Development of a Large-Scale Route to an MCH 1 Receptor Antagonist: Investigation of a Staudinger Ketene–Imine Cycloaddition in Batch and Flow Mode. Org Process Res Dev 2015;19:2067-74. [DOI: 10.1021/acs.oprd.5b00319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
12 Devasthale P, Wang W, Mignone J, Renduchintala K, Radhakrishnan S, Dhanapal J, Selvaraj J, Kuppusamy R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Murphy BJ, Robl JA, Washburn WN. Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies. Bioorganic & Medicinal Chemistry Letters 2015;25:4412-8. [DOI: 10.1016/j.bmcl.2015.09.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
13 Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier G, Markert M, Schindler M, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists—Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414. Bioorganic & Medicinal Chemistry Letters 2015;25:3264-9. [DOI: 10.1016/j.bmcl.2015.05.077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Schindler M, Thomas L, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition. Bioorg Med Chem Lett 2015;25:3270-4. [PMID: 26077492 DOI: 10.1016/j.bmcl.2015.05.074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Oost T, Heckel A, Kley JT, Lehmann T, Müller S, Roth GJ, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RR, Maier GM, Markert M, Thomas L, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. Bioorg Med Chem Lett 2015;25:3275-80. [PMID: 26105194 DOI: 10.1016/j.bmcl.2015.05.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Costantino L, Barlocco D. New perspectives on the development of antiobesity drugs. Future Medicinal Chemistry 2015;7:315-36. [DOI: 10.4155/fmc.14.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Rankovic Z. CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. J Med Chem 2015;58:2584-608. [DOI: 10.1021/jm501535r] [Cited by in Crossref: 279] [Cited by in F6Publishing: 251] [Article Influence: 39.9] [Reference Citation Analysis]
18 Johansson A, Löfberg C. Novel MCH 1 receptor antagonists: a patent review. Expert Opinion on Therapeutic Patents 2014;25:193-207. [DOI: 10.1517/13543776.2014.993382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
19 Wu M, Li Y, Fu X, Wang J, Zhang S, Yang L. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method. Int J Mol Sci 2014;15:15475-502. [PMID: 25257526 DOI: 10.3390/ijms150915475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Philippe C, Haeusler D, Fuchshuber F, Spreitzer H, Viernstein H, Hacker M, Wadsak W, Mitterhauser M. Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system. Eur J Pharmacol 2014;735:177-83. [PMID: 24780646 DOI: 10.1016/j.ejphar.2014.04.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
21 Naufahu J, Cunliffe AD, Murray JF. The roles of melanin-concentrating hormone in energy balance and reproductive function: Are they connected? Reproduction 2013;146:R141-50. [PMID: 23884861 DOI: 10.1530/REP-12-0385] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
22 Qian Y, Conde-knape K, Erickson SD, Falcioni F, Gillespie P, Hakimi I, Mennona F, Ren Y, Salari H, So S, Tilley JW. Potent MCH-1 receptor antagonists from cis-1,4-diaminocyclohexane-derived indane analogs. Bioorganic & Medicinal Chemistry Letters 2013;23:4216-20. [DOI: 10.1016/j.bmcl.2013.05.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
23 Heifetz A, Barker O, Verquin G, Wimmer N, Meutermans W, Pal S, Law RJ, Whittaker M. Fighting obesity with a sugar-based library: discovery of novel MCH-1R antagonists by a new computational-VAST approach for exploration of GPCR binding sites. J Chem Inf Model 2013;53:1084-99. [PMID: 23590178 DOI: 10.1021/ci4000882] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
24 Lim CJ, Kim JY, Lee BH, Oh KS, Yi KY. Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists. Bioorg Med Chem Lett 2013;23:1736-9. [PMID: 23411080 DOI: 10.1016/j.bmcl.2013.01.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]